Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Virginia F Borges

Showing results (21-30 of 154) with videos related to

Pageof 16
Sort By:
International Journal of Cancer|September 5, 2014
Wound healing-like immune program facilitates postpartum mammary gland involution and tumor progressionHolly A Martinson, Sonali Jindal, Clarissa Durand-Rougely, et al.
Experimental Cell Research|May 14, 2013
Developmental windows of breast cancer risk provide opportunities for targeted chemopreventionHolly A Martinson, Traci R Lyons, Erin D Giles, et al.
International Journal of Breast Cancer|December 13, 2018
Innovations in Personalized and Targeted Therapies for Breast CancerEleanor E R Harris, Jennifer De Los Santos, Virginia F Borges, et al.
Clinical Breast Cancer|October 28, 2008
Immunomodulatory therapy in multiple sclerosis and breast cancer risk: a case report and literature reviewRodabe N Amaria, John R Corboy, Christina A Finlayson, et al.
Oncology (Williston Park, N.Y.)|October 18, 2014
Management of young breast cancer patients with de novo genetic mutationsChristine M Fisher, Catherine E Klein, Laxmi A Kondapalli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 23, 2016
21-Gene Recurrence Score Assay As a Predictor of Adjuvant Chemotherapy Administration for Early-Stage Breast Cancer: An Analysis of Use, Therapeutic Implications, and Disparity ProfileJagar Jasem, Arya Amini, Rachel Rabinovitch, et al.
JCO Precision Oncology|March 31, 2022
<i>PIK3CA</i> Mutations Drive Therapeutic Resistance in Human Epidermal Growth Factor Receptor 2-Positive Breast CancerAryana R Rasti, Amy Guimaraes-Young, Farrah Datko, et al.
Oncology (Williston Park, N.Y.)|June 26, 2018
A 35-Year-Old Woman With a Change in HER2 Expression Following Neoadjuvant Chemotherapy for Invasive Breast CancerEricson Stoen, Peter Kabos, Kelly C Borden, et al.
The American Journal of Pathology|September 8, 2015
Myoepithelial cell differentiation markers in ductal carcinoma in situ progressionTanya D Russell, Sonali Jindal, Samiat Agunbiade, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 10, 2018
Mucosal Immunity in the Female Murine Mammary GlandCourtney B Betts, Nathan D Pennock, Breanna P Caruso, et al.
Pageof 16

Showing results (21-30 of 154) with videos related to

Sort By:
Pageof 16
International Journal of Cancer|September 5, 2014
Wound healing-like immune program facilitates postpartum mammary gland involution and tumor progressionHolly A Martinson, Sonali Jindal, Clarissa Durand-Rougely, et al.
Experimental Cell Research|May 14, 2013
Developmental windows of breast cancer risk provide opportunities for targeted chemopreventionHolly A Martinson, Traci R Lyons, Erin D Giles, et al.
International Journal of Breast Cancer|December 13, 2018
Innovations in Personalized and Targeted Therapies for Breast CancerEleanor E R Harris, Jennifer De Los Santos, Virginia F Borges, et al.
Clinical Breast Cancer|October 28, 2008
Immunomodulatory therapy in multiple sclerosis and breast cancer risk: a case report and literature reviewRodabe N Amaria, John R Corboy, Christina A Finlayson, et al.
Oncology (Williston Park, N.Y.)|October 18, 2014
Management of young breast cancer patients with de novo genetic mutationsChristine M Fisher, Catherine E Klein, Laxmi A Kondapalli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 23, 2016
21-Gene Recurrence Score Assay As a Predictor of Adjuvant Chemotherapy Administration for Early-Stage Breast Cancer: An Analysis of Use, Therapeutic Implications, and Disparity ProfileJagar Jasem, Arya Amini, Rachel Rabinovitch, et al.
JCO Precision Oncology|March 31, 2022
<i>PIK3CA</i> Mutations Drive Therapeutic Resistance in Human Epidermal Growth Factor Receptor 2-Positive Breast CancerAryana R Rasti, Amy Guimaraes-Young, Farrah Datko, et al.
Oncology (Williston Park, N.Y.)|June 26, 2018
A 35-Year-Old Woman With a Change in HER2 Expression Following Neoadjuvant Chemotherapy for Invasive Breast CancerEricson Stoen, Peter Kabos, Kelly C Borden, et al.
The American Journal of Pathology|September 8, 2015
Myoepithelial cell differentiation markers in ductal carcinoma in situ progressionTanya D Russell, Sonali Jindal, Samiat Agunbiade, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 10, 2018
Mucosal Immunity in the Female Murine Mammary GlandCourtney B Betts, Nathan D Pennock, Breanna P Caruso, et al.
Pageof 16